Latest

GLP-1

·July 29, 2026·8 min read

Oral Ozempic Cuts Heavy Drinking and Cravings

Oral semaglutide reduces heavy drinking days, daily cravings, and alcohol-related problems in adults with Alcohol Use Disorder.

Featured Neuroscience

·July 24, 2026·9 min read

Future Obesity Drugs to Target Specific Brain Circuits

Using site-specific knockout mouse models, researchers found that GIPR agonists suppress appetite via the brainstem, while GIPR antagonists act in the hypothalamus to release a "brake" on hindbrain satiety.

Featured Neuroscience Psychology

·July 16, 2026·13 min read

GLP-1’s Reduce Binge Eating Symptoms

A new study establishes that GLP-1 receptor agonists significantly reduce core behavioral markers of Binge Eating Disorder, including active binge episodes, loss-of-control eating, and emotional eating.

Featured Neuroscience Visual Neuroscience

·July 14, 2026·10 min read

GLP-1s Linked to Sudden, Rare Vision Loss

Researchers identifies a slight statistical association between GLP-1 receptor agonists (including semaglutide and tirzepatide) and an increased risk of ischemic optic neuropathy.

This shows a brain and pills. One half of the brain is red, implying violence.

Featured Neuroscience Psychology

·June 17, 2026·8 min read

Can GLP-1 Medications Blunt the Path to Violence?

GLP-1 receptor agonists, such as Ozempic and Wegovy, may drastically reduce behaviors linked to violence.

This shows a person running and a brain.

Featured Neuroscience

·June 13, 2026·8 min read

GLP-1 Therapies Silence Spontaneous Physical Activity

A new study demonstrates that adults managing obesity significantly decrease their physical activity after starting GLP-1 receptor agonist medications.

This shows a brain made of gut bacteria.

Featured Neuroscience Psychology

·June 10, 2026·9 min read

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

The GLP-1 agonist liraglutide treats depressive symptoms via a novel microbial pathway.

Featured Neuroscience

·May 22, 2026·8 min read

Study Aims to Break GLP-1 Weight-Loss Plateaus

The weight-loss effects of semaglutide depend on boosting a signaling molecule called cAMP within appetite-regulating neurons in the area postrema.

Featured Neuroscience

·May 12, 2026·7 min read

GLP-1 Drugs Dramatically Reduce “Food Noise” in Weight Loss

GLP-1 medications effectively "turn down the volume" on intrusive food thoughts. In a study of 417 adults, those combining medication with behavioral therapy saw a significantly greater reduction in "food noise" than those using therapy alone, offering a potential neurobiological explanation for the success of these new obesity treatments.

Featured Neuroscience

·May 7, 2026·9 min read

GLP-1 Drugs Found to Directly Rewire Brain’s Reward System

Researchers have discovered a neural pathway connecting the amygdala to dopamine neurons that allows these weight-loss medications to reduce the desire for rewarding foods, offering a new explanation for their effectiveness and their impact on addictive behaviors.

Featured Neurology Neuroscience

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

1 2 3

GLP-1

Oral Ozempic Cuts Heavy Drinking and Cravings

Future Obesity Drugs to Target Specific Brain Circuits

GLP-1’s Reduce Binge Eating Symptoms

GLP-1s Linked to Sudden, Rare Vision Loss

Can GLP-1 Medications Blunt the Path to Violence?

GLP-1 Therapies Silence Spontaneous Physical Activity

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

Study Aims to Break GLP-1 Weight-Loss Plateaus

GLP-1 Drugs Dramatically Reduce “Food Noise” in Weight Loss

GLP-1 Drugs Found to Directly Rewire Brain’s Reward System

GLP-1 Drugs Target the Roots of Dementia

Ozempic Weight Loss Success Varies by DNA

Why Cannabis Can Suddenly Trigger Panic

Can an AI Ever Truly Be “Conscious” in the Eyes of Humans?

Comparing Current Appearance to Past Selves Harms Body Image

Optical Illusion Exposes Blind Spot in AI Vision

Subscribe